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Background and aim: Patient decision a ids for oncological treatment options. provide information on the 
effect on recu rrence rates and /or survival benefit, and on side-effects and/or burden of d ifferent treat-
ment options. However. often uncertainty exists around the probabil ity esti mates for recurrence/survival 
and side-effects w hich is too relevant to be ignored. Evidence is lacking on the best way to communicate 
these uncertainties. The aim of th is study is to develop a method to incorporate uncertai n ties in a patient 
decision aid for breast cancer patients to support their decision on radiotherapy. 
Methods: Firstly, qualitative interviews were held with patients and health care professiona ls. Second ly, 
in the development phase, th inking a loud sessions were organized w ith fou r patients and 12 hea lth care 
professionals, individual and group-wise. 
Results: Consensus was reached on a pictograph illustrating the whole ra nge of uncertainty for loca l 
recurrence risks, in combination w ith textua l explanation that a more exact personalized risk would be 
given by their own physician. The pictograph consisted of 100 female icons in a 10 x 10 array. Icons with a 
stepwise gradient co lor indicated the uncertainty margin. The prevalence and severity of possible side-
effects were explained using verbal labels. 
Conclusions: We developed a novel way of visual izing uncertainties in recurrence rates in a patient 
decision aid . The effect of th is way of communicating risk uncerta inty is currently be ing tested in the 
BRASA study (NCT03375801 ). 
© 2020 The Author(s). Publ ished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
Abbreviations: SDM, shared decision making: HP, health care professionals: PtDA, patient deci sion aid; DCS, ductal carcinoma in situ: BCSS, breast cancer specific survival ; 
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1. Introduction 
In health care, the best treatment for the individual patient is a 
tradeoff between the medical advantages and disadvantages of 
different treatment options and the personal values and prefer-
ences of the patient. This tradeoff is most relevant in preference-
sensitive decisions: treatment decisions where no best treatment 
exists [ 1- 3 ]. 
Some breast cancer patients, e.g. with an intermediate risk local 
recurrence risk (LRR), face such a preference-sensitive decision 
when deciding on adjuvant radiotherapy. The benefits of radio-
therapy consist of a decrease in the risk of recurrence and some-
times a small survival benefit [4- 9 ). The disadvantages are possible 
side-effects and treatment burden. In many cases however, the 
exact recurrence risks are unknown. This is amongst other reasons 
due to literature based on outdated trials ; breast cancer clinical 
trials having a long follow-up whilst new treatment options 
develop fast. Another reason is that clinical trials use strictly defined 
patient categories and patients do not always fit in the trial popu-
lation [7 ]. Therefore, estimated recurrence risks are surrounded by 
an unce1tainty margin. Some guidelines reflect this unce1tainty, 
advocating shared decision making with the patient [5). 
There are two levels of uncertainty. First-order/a leatory uncer-
tainty, is the uncertainty of an event taking place in the future. The 
risk estimate is known on group level, but it is difficult to predict 
whether it will happen yes or no in the individual patient. Second-
order/epistemic uncertainty, is the uncertainty around the risk 
estimates [10). There is even uncertainty on the risk estimate on 
group level. Little is known on the best way to communicate risks 
and uncertainties to patients [11.12 ]. Risks and aleat01y uncertainty 
are hard to understand for patients [13). Communicating epistemic 
uncertainty is even a bigger challenge. Therefore, if clinicians 
communicate risks to patients, point estimates are commonly used. 
From ethical and medical-legal considerations, it can be argued 
though that patients should be fully informed on their treatment 
options including the uncertainty around these point estimates 
[14.15). 
There is also epistemic uncertainty around the prevalence and 
severity of the side-effects of radiotherapy for breast cancer pa-
tients. First, the available literature mentioning prevalence and 
severity of side-effects is inconsistent, partly due to the use of 
different scoring systems to record side-effects [16). Consequently, 
literature gives a wide range of prevalence and severity estimates 
[17,18 ]. Second, long-term side effects occur months to many years 
after irradiation, such that not all side-effects may be captured by 
registries and that by the time late side-effects occur, new treat-
ments have become the standard [19). Third, patient and treatment 
characteristics influence the risk of developing certain side-effects, 
making it harder to translate general risk estimates to specific es-
timates for individual patients [20 ]. 
A patient decision aid (PtDA) may be used to support the deci-
sion process and communication of risks and uncertainty [21 ]. 
PtDAs are tools that provide evidence based information on the 
advantages and disadvantages of different treatment options, make 
clear that they can decide between these options, and help patients 
to clarify which attributes are most important to them when 
making a medical decision [21 ]. However, there is no clear guide-
line on how uncertainty should be communicated in a PtDA. 
Therefore, there is large heterogeneity in how this is done [22 ]. In a 
review by Bansback et al. [23 ) only half of the tools described 
epistemic uncertainty. If epistemic uncertainty was mentioned it 
was mostly referred to in a qualitative way (large, small etc.). 
Although it might seem that these qualitative labels are better-
understood compared to quantitative risks [24), it is known that 
patients interpret qualitative labels in very different ways. For 
example Freeman describes that the term "common" in an infor-
mation leaflet is used for a side-effect occurring in 1-10% of cases, 
while doctors interpret common as something occurring in 25% of 
cases and patients in 50% of cases [15 ]. 
Although several PtDAs have been developed for early stage 
breast cancer patients, deciding on different treatment options, to 
our knowledge there are only two PtDAs for breast cancer patients 
deciding on radiotherapy [25 ]. Both have been developed in Canada 
for patients deciding on radiotherapy after lumpectomy and do not 
include information on uncertainty around the point estimates or 
side-effects [26,27]. Therefore, the primary objective of this study 
was first to assess opinions and attitudes of breast cancer patients 
and professionals on if, and how, to communicate uncertainties in 
recurrence rates, survival, and side-effects. The second objective 
was to incorporate this knowledge in a PtDA for breast cancer pa-
tients to support their decision on radiotherapy. 
2. Methods 
For the content of the PtDA we followed the guidelines of the 
International Patient Decision Aid Standards (IPDAS) [28,29 ]. From 
the start, it was clear that the PtDA had to be made for four different 
pathways: 
1) Patients with low risk ductal carcinoma in situ (DCIS) after 
breast conserving surgery deciding on (partial ) breast radio-
therapy or no radiotherapy. 
2) Patients with low risk invasive ductal carcinoma after breast 
conserving surgery deciding on (partial ) breast radiotherapy or 
no radiotherapy. 
3) Patients with intermediate risk breast cancer after mastectomy 
deciding on thoracic wall radiotherapy or no radiotherapy. 
4) Patients with intermediate risk breast cancer after breast 
conserving surgery deciding on whole breast radiotherapy with 
or without an additional boost dose to the tumor bed. 
2.1. Phase one: qualitative interviews 
A qualitative study was conducted to explore the patients and 
health care professionals (HPs ) views on important attributes for 
shared decision making for breast cancer patients deciding on 
radiotherapy [30]. For this paper, we only report the data on the 
communication of uncertainties. Data on other attributes and 
preferences are published elsewhere [31 ]. 
2.2. Phase two: alpha testing the risk communication part of the 
PtDA 
With information derived from the interviews, the research 
team developed a draft version of the risk communication part of 
the PtDA. The PtDA was developed with input from both patients 
and HPs in different rounds (Fig. 1 ). 
2.2.1. Patient advocates recruitment 
Patient advocates were recruited through the national breast 
cancer association, the patient adviso1y group of the national breast 
cancer research group and through the patient advis01y board of 
Maastro, one of the participating hospitals. 
2.2.2. Health care professionals' recruitment 
Radiation oncologists, surgeons, radiotherapy physician assis-
tants and trial managers, all specialized in breast cancer, from 15 
radiotherapy centers in the Netherlands were invited through 
personal contacts. 
D.B. Raphael et al. / The Breast 51 (2020) 105- 113 107 
2.2.3. Development rounds 
The draft version contained a PowerPoint presentation with a 
schematic concept of the PtDA accompanied by a Word document 
for patient advocates feedback. In round 1, the feedback was used to 
make a first online PtDA version. In round 2, a live group meeting 
with HPs and patent advocates was organized to discuss this online 
version. The content and layout of the PtDA was discussed until 
consensus was reached in the most important topics. In round 3, 
thinking aloud sessions [32] were organized with new drafts of the 
PtDA: Patient advocates reviewed the PtDA whi le speaking out loud 
what they thought and understood. With this feedback a pre-final 
version was developed. Round 4 consisted of a second live group 
meeting with HPs and patients. Here the pre-final version of the 
PtDA was discussed until consensus was reached, on a version that 
































Teleconference with two patient 
advocates who reviewed the first 
draft version 
Two patient advocates and one 
project leader of patient -
association present 
Three rounds of thinking out loud 
sessions with different versions of 
the decision aid with three patient 
advocates 
Two patient advocates and one 
3. Results 
3.1. Phase one: qualitative interviews 
Most patients and HPs agreed that recurrence risks, smvival 
data and side-effects in the PtDA should be communicated. Whi le 
Qualitative study, interviews 
with patiens and health care 
professionals 
I 
Development of a prototype (in 
powerpoint) 
First online PtDA version 
Live group meeting with the 
project team, health care - Nine radiation oncologists and 
professionals and patient one physician assistant present 
advocates . 
Adjustments to the online 
PtDA version 
I 
Pre final version of PtDA 
I 
Live group meeting with the 
Five radiation oncologists and 
project leader of patient - project team, health care - three trial managers present 
association present 
professionals and patient 
advocates 
Final version of PtDA (alpha 
testing) 
Multi-center trial; BRASA study 
Fig. 1. Overview of the development of the Patient decision aid. 
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patients were only aware of aleatory uncertainty for recurrence 
risks, HPs also worried on how to communicate epistemic uncer-
tainty. While patients did not express a specific preference for risk 
format, HPs agreed on communicating risks in a visual way. The 
treatment burden was not mentioned as an important attribute to 
decide on radiotherapy or not. The most relevant side-effects to 
both patients and HPs were extracted from the interviews [31 ]. 
3.2. Phase two: alpha testing the risk communication part of the 
PtDA 
LRR and breast cancer specific survival (BCSS ) were illustrated 
by a pictograph, combined with textual explanation of the LRR/ 
BCSS: x out of 100 women will have a local recurrence in 10 years 
(Fig. 2) and x out of 100 women will die from breast cancer in 10 
years. No uncertainty was communicated. 
Side-effects were divided in short term (red and sensitive skin, 
edema, tiredness, and pain of the breast) and long-term side-effects 
(fibrosis and change in breast shape, edema, (dark) skin dis-
colouration, pain, rib complications, heart problems and lung 
problems). Due to lack of relevant data, no quantification on 
probability could be given other than that side-effects could occur. 
In round 1 patients understood the risks communicated on the 
pictographs. The data on BCCS were experienced as confronting, 
although patients thought that it was important to communicate. 
The online version of the PtDA was developed together with an 
e-learning company (EyeSpirations, Amersfoort, The Netherlands ) 
(Fig. 3 ). 
During the live group meeting in round 2, with both patients 
How big is the risk of recurrence? 
and HPs there was agreement on the 10-year time frame for LRR. 
For pathway 2 consensus was reached on point estimates. A debate 
emerged on the LRR estimates of the other three pathways. It was 
argued that no estimates could be given since the LRR depend on 
individual patient, tumor and treatment characteristics but vali-
dated nomograms are lacking. The relative risk reduction is inde-
pendent of individual characteristics. Therefore, there was 
consensus on mentioning both the absolute and the relative 
reduction in recurrence risk in combination with a pictograph. The 
absolute recurrence risk was mentioned as a range in risk reduction 
with an explanation that the patient's clinician would personalise 
the patient's LRR. Two options were suggested for the pictographs. 
The first option was to use fading colours in the 10 x 10 pictograph 
to indicate a given risk with its uncertainty margin. The second 
option was to show two different pictographs, one with the 
smallest estimated recurrence risk, and another with the highest 
estimated recurrence risk. Another debate emerged on how to 
communicate survival risks. It was argued that BCSS is not prefer-
able the patient is mainly interested in overall smvival expectancy. 
Overall survival however, is impossible to generate for the whole 
group since it also depends on patient characteristics, such as age, 
and co-morbidity, In Pathway 1, 2 and 4 no gain in smvival is ex-
pected from radiotherapy, therefore, it was decided to mention this 
fact in words without putting an overall quantitative figure on it. 
For the intermediate risk breast cancer after mastectomy (pathway 
3) there is assumed to be a small in survival benefit (i.e. <2- 3%), 
which was described in this way in the PtDA. 
Consensus on the information on the side-effects was reached 
by adding only qualitative labels to indicate an estimation of the 
After 10 years, 10 out of 100 woman are 
estimated to experience a local 
recurrence 
• Breast cancer recurrence 
No recurrence 
Fig. 2. Pictograph in first draft version of the PtDA: Local recurrence risk for low risk breast cancer after breast conserving surgery without radiotherapy. 
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> 
{~ Summary 
Recurrence Dea:r- ris 
Recurrence risk after 10 years 
WITHOUT rad iotherapy 
+/-10 out of 100 woman 
Sercefi s Di:.actvartc_gt?.S 
WITH rad iotherapy 
+/- 3 out of 100 woman 
Fig. 3. Study-logo adapted pictographs with local recurrence risk with and without radiotherapy, in the first online version: Local recu rrence risk fo r low risk breast cancer after 
breast conserving surgery with and without radiotherapy. 
prevalence and severity of the possible side-effects. There was 
agreement that no estimates on frequency or severity of the ex-
pected side effects could be given, since there is a large variation in 
experienced side effects between patients and there is no adequate 
data available to predict this outcome for the individual patient. For 
the late side effects, distinction was made between common 
(fibrosis and change in breast shape, edema and pain) and rare 
side-effects ((dark) skin discolouration, rib complications, heart 
problems and lung problems). Severity of the side-effects was 
qualified as varying between patients between almost no discom-
fort to very annoying. Smoking was added as an important risk 
factor for heart problems and secondary lung cancer after breast 
irradiation. Also, more information was added to the consequences 
of the different side-effects. 
For the thinking aloud sessions in round 3, new pictorial charts 
were made. For pathway 2, pictographs with point estimates were 
made (Fig. 4). For the other three pathways, there was a preference 
for the pictographs with fading colours, ultimately a choice was 
How h,g ,~ ;he re<urrence 
ri-,k) 
Radio apy reduc ~ t e local ecurre ce rate W1 h a ctor 3 Che on 
the image b low for more information 
♦ • Bn .3\I c tncer 
+ • brc"d'>t <an< ·r br I cam~ 
Fig. 4. Pictograph without uncertainty range befo re round 3: 10 years local recurrence risk fo r low risk breast cancer after breast conserving surgery with and without radiotherapy, 
with the BRASA logo pictographs replaced. 
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made for orange and purple icons. The textual explanation was 
placed on the virtual back of the pictographs. They were visualized 
when patients clicked on the pictographs (Fig. Sa and b). It was 
proposed to add more possible treatment options for the side-
effects to the PtDA, such as physiotherapy. 
In the second live meeting in round 4, the fading colouring 
indicating the uncertainty margin of the female icons was found to 
be unclear since the contrast was lost because of the fad ing scheme. 
Ho,,, b,g ,~ ,he recurrence 
r1~~ "') 
Ho. big IS h b ~· 
cancer re<urrenc ns' 7 
Ho,\< b,g ,~ !he recurrence 
r1:,l:, 
a 
Rad th rapy r d ces h loc rec ir era a 1act0f 3 Che on 
he 1mag b low for mor information 
• Br ,,,.I c, r-r 
• o br r.l .in(,,,-
b 
Rad:o erapy red ces he loc., recurre ce r h a fac. or 3 Che on 
the ,mage below for more ,nform hon 
WITHOUT rad1oth rapy WITH radiotherapy 
O the woman treated 
WHITHOUT radiotherapy 
10-30 out of 100 woman 
will have a local 
recurrence after 10 
years. In the consultation 
111th your chnrcian 
he/she will tell you if 
your personal chances of 
a local r currence 1s 
closer to 10 ou of 100 
or closer o 30 ou of 
l00woman. 
Of the woman trea ed 
WITH radiotherapy 3-10 
out of 100 woman will 
have a local recurrence 
after 10 years. In the 
consultation with your 
dinician he/she will tell 
you 1f your personal 
chances of a local 
recurrence is closer to 3 
out of 100 woman or 
closer to 10 out of 100 
J0man. 
Fig. 5. a Turning pictograph with fading colours: 10 years Local recurrence risk intermediate risk breast cancer after mastectomy with and without radiotherapy.Sb Turning 
pictograph with textual explanation on the back: 10 years Local recurrence risk intermediate risk breast cancer after mastectomy with and without radiotherapy. 
D.B. Raphael et al. / The Breast 51 (2020) 105- 113 111 
It was proposed to adjust the fading colouring into changing the 
color of the icons step by step from orange to purple (Fig. 6 ), leading 
to the final version of the pictograph for the PtDA. 
4. Discussion 
In the development of a PtDA for breast cancer patients deciding 
on adjuvant radiotherapy, we created a way to communicate 
epistemic uncertainties when estimating LRR. Consensus was 
reached between HPs and patients on a pictograph illustrating the 
whole range of uncertainty, in combination with textual explana-
tion and information that their own physician would estimate a 
more exact risk for the individual patient. The final pictograph 
consisted of 100 female icons in a 10 x 10 array. The female icons 
indicating the uncertainty margin of the LRR were displayed as step 
by step decolouring icons, from orange to purple (Fig. 6). The absent 
or small gain in survival benefit of radiotherapy was communicated 
by words without a quantitative number. Due to lack of reliable 
evidence, the prevalence and severity of the possible side-effects 
was only expressed in qualitative labels. 
We used pictographs, they are known to improve patients un-
derstanding in risk communication [ 15,33- 36]. Textual risk 
communication is better understood in combination with visual 
support [13 ]. The guideline on risk communication for PtDAs, 
developed by the IPDAS collaboration, advises to use natural fre-
quencies and clear denominators over time and to be consistent, 
using the same denominator in all examples [34]. The first online 
version of the decision aid was therefore consistent with the known 
literature. 
In three of the four pathways, no consensus was reached on an 
absolute value of a point-estimate for the LRR. Consequently, we 
had to develop a way of communicating the epistemic uncertainty. 
Although some effort has been put in researching how to 
communicate aleatory uncertainty, Jess research has been done on 
how to communicate epistemic uncertainty [22,23,34,37,38]. 
HO\\ b,g ,~ :he> recurrenc,0 
rd.J 
Communicating epistemic uncertainty may lead to more cancer 
worries and may reduce trust, although available literature is 
inconsistent to this point (37,39]. Communicating epistemic un-
certainty in a way that will not cause a negative impact therefore 
seems important. We are not aware of other examples of PtDAs 
communicating epistemic uncertainty in a visual way. In our study 
consensus was reached on two-tone icons, showing the whole 
width of epistemic uncertainty in combination with textual 
explanation, and with the explanation that their own physician 
would inform them further. Whether this is an effective method of 
communicating epistemic uncertainty in a PtDA needs further 
investigation in a clinical setting. At this moment, this way of 
communicating epistemic uncertainty is being used in a pre-and 
post-intervention study, the BRASA-study (clinical.trials.gov: 
NCT03375801 ). In this study, we ask patients to fill out question-
naires to test their knowledge on their disease, to evaluate the 
PtDA, and the process of shared decision-making. 
As discussed earlier, qualitative risk labels are well understood 
by patients but have the disadvantage of being interpreted in 
different ways (15]. No clear data are available on the prevalence 
and severity of side-effects of current radiotherapy for breast can-
cer patients. There is difference in the definition endpoint of side-
effects and different studies use different parameters to measure 
the same outcome. For example to measure change in shape due to 
fibrosis as a consequence of radiotherapy, cosmetic outcome has 
been evaluated in several trials. Some studies use patient reported 
outcome measures while others use scoring systems scored by 
physicians or even computer systems evaluating photographs 
[16,40]. Low agreement has been found between these different 
methods [41,42 ]. Consequently, we could not include reliable esti-
mates for side-effects in the PtDA, not even using uncertainty 
margins. Although we were aware of the shortcoming of commu-
nicating risks by qualitative labels, we felt we had no other option 
and consensus was reached on using qualitative labels when 
communicating both the frequency as well as the severity of the 
t • Bit', I < IY 
t,1 .... t{t'f 
Fig. 6. Pictograph with uncertainty margins, final version of PtDA: 10 years Local recurrence risk fo r intermediate risk breast cancer after mastectomy with and without 
radiotherapy. 
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possible side-effects. Further research is needed to overcome this 
problem. With modern radiotherapy techniques radiotherapy dose 
to the heart and lungs have been reduced, reducing long-term side 
heart disease and lung cancer. For patients who smoke these risks 
are substantially higher than for non-smokers [20]. Since in this 
smoker-group the disadvantages might therefore outweigh the 
advantages, this was mentioned separately. 
Strengths and limitations: we were only able to include four 
patient advocates in the development team who were mostly 
highly educated. Patient advocates are trained patients [43 ] and 
from literature we know that both patients and HPs involved in the 
development of a PtDA have a learning curve. Patient advocates are 
in a different situation, than patients looking at the PtDA for the 
first time when making a decision on their treatment [44]. Despite 
this shortcoming, the patient advocates took an active part in the 
development team. 
Conclusion: We incorporated pictographs with stepwise 
gradient color icons indicating the uncertainty margin in combi-
nation with text, to communicate epistemic uncertainty in a PtDA 
breast cancer patients deciding on radiotherapy. The prevalence 
and severity of possible side-effects were communicated by qual-
itative labels. Currently the PtDA is being tested in a multi-center, 
pre-and post-implementation study in the Netherlands, the 
BRASA study. 
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